Hemispherx Announces Data Showing Inhibition of Ebola by Ampligen(R) Enlarged by Howard University Research
09. Dezember 2014 09:51 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Dec. 9, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today that it has received a new research report (dated December 5,...
Centers for Disease Control Urges Preparation for an Active Seasonal Flu Season
16. Dezember 2013 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Dec. 16, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announced that the company will accelerate its experimental program for a new...
FDA Authorizes Expansion of Ampligen/FluMist Intranasal Clinical Trial Designed to Elicit Potential Protection Against Many Pre-Pandemic Influenza Viruses
09. Dezember 2013 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Dec. 9, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced that its Phase 1/2 clinical trial at the University of Alabama...
Hemispherx Biopharma Appoints New Chief Financial and Chief Accounting Officers
04. Dezember 2013 07:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Dec. 4, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced that the Board has appointed Thomas Equels as the new Chief...
Hemispherx Biopharma and the University of Pittsburgh Collaborate on a Novel Chemokine-Modulatory Program for Cancer Immunotherapies With Ampligen(R) as a Key Component
02. Dezember 2013 07:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced that it is supporting the University of Pittsburgh's National...
Hemispherx Biopharma Sponsors Chronic Fatigue Syndrome Conference at Mount Sinai Medical Center in New York
19. November 2013 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its sponsorship of the Conference on "Diagnosis, Treatments and New Developments in ME and CFS" ("Myalgic...
Hemispherx Biopharma Announces Financial Results for the Three Months Ended September 30, 2013
08. November 2013 16:24 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Nov. 8, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the three months ended September 30, 2013. The net loss (including non-cash...
Hemispherx Biopharma Reports on Annual Stockholder Meeting
18. Oktober 2013 13:10 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Oct. 18, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc. (NYSE MKT:HEB) announced that it held its 2013 Annual Meeting of Stockholders on October 18, 2013. Final voting results will...
Hemispherx Biopharma's 2013 Stockholder Annual Meeting Proposal 4 Removed From Stockholder Consideration
03. Oktober 2013 13:46 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company") announced that its Board of Directors has decided not to seek Stockholder approval regarding...
Hemispherx Biopharma's 2013 Stockholder Annual Meeting Set
18. September 2013 16:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 18, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company") will hold its Annual Meeting of stockholders on Friday, October 18, 2013, at 10 a.m. EDT, in...